Deal Dispatch: Morgan Stanley Buys Vinyl Equity, Fox Completes Roku Acquisition, Children's Place Files for Chapter 11
Major M&A deals this week include: CorMedix buys Heron for $145M and Craveworthy Brands buys New England Authentic Eats.
Last updated: 2026-11-14 18:45:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Heron Therapeutics, Inc. (HRTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.31, with a market capitalization of $62.01M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.26 to $1.58. This page covers its latest market performance, valuation, price trends and company information.
$62.01M | |
$0.36 | |
$0.36 | |
$0.31 | |
$0.33 | |
2.34M | |
4.58M | |
-- | |
$1.58 | |
$0.26 | |
-- | |
-- |
Heron Therapeutics, Inc. (HRTX) last closed at $0.31 as of 2026-11-14 00:51:00, down 4.33% ($0.01) from the previous close of $0.33.
During the latest regular trading session, HRTX traded between $0.31 and $0.36, with a volume of 2.34M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Heron Therapeutics, Inc. (HRTX) moved from $0.28 to $0.31, representing a gain of 11.07% ($0.03).
The stock traded between $0.27 and $0.42 during the period. The latest price is near the lower end of the 7-day range, indicating strong upward.
The average daily volume was 23.94 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 3.8%
HRTX is currently trading at $0.31, placing it 3.8% of the way from its 52-week low of $0.26 to its 52-week high of $1.58. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 128 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Heron Therapeutics, Inc. and HRTX stock.
Major M&A deals this week include: CorMedix buys Heron for $145M and Craveworthy Brands buys New England Authentic Eats.
Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3 earnings report
Eligible investors can buy real shares of Heron Therapeutics, Inc. (HRTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to HRTX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between HRTX shares and USD.
HRTX Shares to USD
1.00 HRTX shares = 0.311 USD
Calculations are estimates based on the latest available price and are for reference only.